Listed by the USPTO as GEORGE, DENNIS CHERIAN
Tech Center 1600 • Art Units: 1644
This examiner grants 43% of resolved cases
GEORGE, DENNIS CHERIAN has resolved 14 cases in Tech Center 1600 and Art Unit 1644. The allowance rate is 42.9%, and the median time to allowance is 1323 days. The interview lift is 72.7%, the largest recorded prosecution factor in this profile, making interview preparation especially relevant for applications before this examiner.
The listed companies are Takeda Pharmaceutical Company Limited, Memorial Sloan Kettering Cancer Center, and BIOND BIOLOGICS LTD. The leading firms are BAKER BOTTS L.L.P., Biospark Intellectual Property Law, and COOLEY LLP. The limited case volume means these figures should be used as directional guidance.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17416859 | T-CELL RECEPTOR MODIFIED OBJECT | Final Rejection | Takeda Pharmaceutical Company Limited |
| 17915761 | IMMUNOMODULATORY COMPOSTIONS AND USE THEREOF | Non-Final OA | BIOND BIOLOGICS LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy42.9% of resolved applications examined by Dennis Cherian George were allowed (14 resolved cases), compared with 35.9% across Art Unit 1644 over the last five years.
This examiner's interview lift is +72.7 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Dennis Cherian George took 1,323 days on average from filing to allowance.
Dennis Cherian George examines applications in Art Unit 1644 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
